Vimta Labs Limited

NSE VIMTALABS.NS

Vimta Labs Limited EBITDA for the year ending March 31, 2024: USD 10.87 M

Vimta Labs Limited EBITDA is USD 10.87 M for the year ending March 31, 2024, a -6.73% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Vimta Labs Limited EBITDA for the year ending March 31, 2023 was USD 11.65 M, a 10.21% change year over year.
Vimta Labs Limited EBITDA for the year ending March 31, 2022 was USD 10.57 M, a 44.04% change year over year.
Vimta Labs Limited EBITDA for the year ending March 31, 2021 was USD 7.34 M, a 82.02% change year over year.
Vimta Labs Limited EBITDA for the year ending March 31, 2020 was USD 4.03 M, a -51.78% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NSE: VIMTALABS.NS

Vimta Labs Limited

CEO	Dr. Sivalinga Prasad Vasireddi
IPO Date	Dec. 15, 2005
Location	India
Headquarters	Plot Nos. 141/2 & 142, IDA, Phase II
Employees	1,428
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Research & Consulting

Description

Vimta Labs Limited provides contract research and testing services in India and internationally. It offers laboratory, food and water testing and analysis, preclinical and clinical research, biological molecule structural and functional analysis, environmental assessment, and clinical reference laboratory services. The company serves pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and various other industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.

Key trends

Past 5 years